Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients

Journal of the American Society of Nephrology

Volumn 9, Issue 1, 1998, Pages 97-104

  Lebel, Marcel ^a   Kingma, Iris ^a   Grose, John H ^a   Langlois, Serge ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; CATECHOLAMINE; CELLULOSE ACETATE; ENDOTHELIN 1; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; RENIN; SODIUM;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DRUG EFFECT; EXTRACELLULAR SPACE; FEMALE; HEART OUTPUT; HEMATOCRIT; HEMODYNAMICS; HORMONAL THERAPY; HUMAN; HYPERTENSION; MALE; PLASMA VOLUME; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC VASCULAR RESISTANCE; UREMIA;

EID: 0031985646     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW: Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens 3: 947-955, 1990
2. Abraham PA, Macres MG: Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 2: 927-936, 1991
3. Canadian Erythropoietin Study Group: Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Am J Nephrol 11: 23-26, 1991
4. Anastassiades E, Howarth D, Howarth J, Shanks D, Waters H, Hyde K, Yin JL, Geary C, Gokal R: Influence of blood volume on the blood pressure of predialysis and peritoneal dialysis patients treated with erythropoietin. Nephrol Dial Transplant 8: 621-625, 1993
5. Abraham PA, Opsahl JA, Keshaviah PR, Collins AJ, Whalen JJ, Asinger RW, McLain A, Hanson G, Davis MG, Halstenson CE: Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. Am J Kidney Dis 16: 438-446, 1990
6. Hori K, Onoyama K, Iseki K, Fujimi S, Fujishima M: Hemodynamic and volume changes by recombinant human erythropoietin in the treatment of anemic hemodialysis patients. Clin Nephrol 33: 293-298, 1990
7. Carlini R, Obialo CI, Rothstein M: Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 6: 103-107, 1993
8. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992
9. Heidenreich S, Rahn K-H, Zidek W: Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 39: 259-265, 1991
10. Cranston WI, Brown W: Diurnal variations on plasma volume in normal and hypertensive subjects. Clin Sci 25: 107-112, 1963
11. Lebel M, Kingma I, Grose JH, Langlois S: Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in normotensive and in untreated borderline hypertensive hemodialysis patients. Am J Hypertens 9: 545-551, 1994
12. Pickering TG, Blank SG: Blood pressure measurement and ambulatory blood pressure monitoring: Evaluation of available equipment. In: Hypertension: Pathophysiology, Diagnosis and Management, edited by Laragh JH, Brenner BM, New York, Raven, 1990, pp 1429-1441
13. Rizzoni D, Muilsan ML, Montani G, Zulu R, Calebich S, Agabiti-Rossi E: Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring. Am J Hypertens 5: 180-186, 1992
14. Lebel M, Grose JH: Angiotensin II effect on plasma steroids in selective hypoaldosteronism. Horm Metab Res 14: 432-436, 1982
15. Lebel M, Grose JH, Kingma I, Langloise S: Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients: Effect of subcutaneous erythropoietin replacement therapy. Clin Exp Hypertens 16: 565-575, 1994
16. Peuler JD, Johnson GA: Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 21: 625-636, 1977
17. Lebel M, Grose JH, Blais R: Alteration of the volume-renin component in borderline essential hypertension. Clin Exp Hypertens 3: 39-54, 1981
18. Chaplin H Jr, Mollison PL: Correction for plasma trapped in red cell column of hematocrit. Blood 7: 1227-1238, 1952
19. Lebel M, Grose JH, Blais R: Abnormal relation of extracellular fluid volume and exchangeable sodium with systemic arterial pressure in early borderline essential hypertension. Am J Cardiol 54: 1267-1271, 1984
20. Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C: Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 295: 1017-1020, 1987
21. Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S: Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am J Med 94: 401-406, 1993
22. van de Borne P, Tielemans C, Vanherweghem JL, Degaute JP: Effect of recombinant human erythropoietin therapy on ambulatory blood pressure and heart rate in chronic haemodialysis patients. Nephrol Dial Transplant 7: 45-49, 1992
23. Baumgart P, Walger P, Gemen S, von Eiff M, Raidt H, Rahn K-H: Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation. Nephron 57: 293-298, 1991
24. Portaluppi F, Montanari L, Massari M, Dichiara V, Capanna M: Loss of nocturnal decline of blood pressure in hypertension due to chronic renal failure. Am J Hypertens 4: 20-26, 1991
25. Mayer G, Hörl WH: Cardiovascular effects of increasing hemoglobin in chronic renal failure. Am J Nephrol 16: 263-267, 1996
26. Evans RW, Rader B, Manninen DL: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin: Cooperative Multicenter EPO Clinical Trial Group. JAMA 263: 825-830, 1990
27. Mayer G, Thum J, Cada EM, Strummvoll HK, Graf H: Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 34: 525-528, 1988
28. Barany P, Pettersson E, Ahlberg M, Hultman E, Bergström J: Nutritional assessment in anaemic haemodialysis patients treated with recombinant human erythropoietin. Clin Nephrol 35: 270-279, 1991
29. Schaefer RM, Leschlke M, Strauer BE, Heidland A: Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. Am J Nephrol 8: 449-453, 1988
30. Mayer G, Stefenelli TH, Cada EM, Thum J, Stummvoll HF, Graf H: Blood viscosity and hemodynamic parameters in dialysis patients treated with human recombinant erythropoietin. Lancet 1: 351-352, 1988
31. Lim VS, DeGowin RL, Zabala D, Kirchner PT, Abels R, Perry P, Fangman J: Recombinant human erythropoietin treatment in pre-dialysis patients: A double-blind placebo-controlled trial. Ann Intern Med 110: 108-114, 1989
32. Kaupke CJ, Kim S, Vaziri ND: Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 4: 1874-1878, 1994
33. Muller R, Steffen HM, Brunner R, Saric J, Pollok M, Baldamus CA, Kaufmann W: Changes in the alpha adrenergic system and increase in blood pressure with recombinant human erythropoietin therapy for renal anemia. Clin Invest Med 14: 614-622, 1991
34. Ono K, Hisahue Y: The rate of increase in hematocrit, humoral vasoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion. Clin Nephrol 37: 23-27, 1992
35. Eggena P, Willsey P, Jamgotchian N, Truckenbrod L, Hu MS, Barrett JD, Eggena MP, Clegg K, Nakhoul F, Lee DBN: Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 261 : E642-E643, 1991
36. Kokot F, Wiecek A, Grzeszczak W, Klin M: Influence of erythropoietin treatment on plasma renin activity, aldosterone, vasopressin and atrial natriuretic peptide in haemodialyzed patients. Miner Electrolyte Metab 16: 25-29, 1990
37. Hasegawa K, Matsushita Y, Inoue T, Morii H, Ishibashi M, Yamaji T: Plasma levels of atrial natriuretic peptide in patients with chronic renal failure. J Clin Endocrinol Metab 63: 819-822, 1986
38. Sasagawa I, Nakada T, Hashimoto T, Kubota Y, Suzuki H, Sawamura T: Change in haemoglobin concentration, haematocrit and vasoactive hormones in haemodialysis patients with erythropoietin-associated hypertension. Int Urol Nephrol 26: 237-243, 1994
39. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT: Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91: 3974-3978, 1994
40. Carlini PG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M: Recombinant human erythropoietin increases endothelin-1 release by endothelial cells. Kidney Int 43: 1010-1014, 1993
41. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PF, Schneider B, Waldhausl W, Binder BR: Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267: 16066-16068, 1992